{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:19:04Z","timestamp":1787242744369,"version":"build-2736575974"},"reference-count":26,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,20]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>FLAG-IDA (fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubicin) with venetoclax shows promise as frontline pediatric acute myeloid leukemia therapy. In 12 patients treated at MD Anderson, most achieved remission with good early survival outcomes, and many proceeded to transplant. Common toxicities included cytopenias, comparable to previous regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025029391","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T18:11:14Z","timestamp":1758305474000},"page":"2608-2611","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML"],"prefix":"10.1182","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8336-8766","authenticated-orcid":false,"given":"Reeja","family":"Raj","sequence":"first","affiliation":[{"name":"1Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0072-8603","authenticated-orcid":false,"given":"Samanta","family":"Catueno","sequence":"additional","affiliation":[{"name":"1Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9146-4702","authenticated-orcid":false,"given":"Amber","family":"Gibson","sequence":"additional","affiliation":[{"name":"1Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2297-9670","authenticated-orcid":false,"given":"David","family":"McCall","sequence":"additional","affiliation":[{"name":"1Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2978-2267","authenticated-orcid":false,"given":"Miriam B.","family":"Garcia","sequence":"additional","affiliation":[{"name":"1Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"Nunez","sequence":"additional","affiliation":[{"name":"1Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6411-8353","authenticated-orcid":false,"given":"Michael","family":"Roth","sequence":"additional","affiliation":[{"name":"1Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-0610","authenticated-orcid":false,"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[{"name":"2Division of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4819-5276","authenticated-orcid":false,"given":"Priti","family":"Tewari","sequence":"additional","affiliation":[{"name":"3Division of Pediatrics, Pediatric Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4339-8683","authenticated-orcid":false,"given":"Ghayas C.","family":"Issa","sequence":"additional","affiliation":[{"name":"2Division of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Farhat","sequence":"additional","affiliation":[{"name":"2Division of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2817-8890","authenticated-orcid":false,"given":"Jeremy","family":"Connors","sequence":"additional","affiliation":[{"name":"3Division of Pediatrics, Pediatric Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4869-8818","authenticated-orcid":false,"given":"Irtiza","family":"Sheikh","sequence":"additional","affiliation":[{"name":"3Division of Pediatrics, Pediatric Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Nishida","sequence":"additional","affiliation":[{"name":"2Division of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0914-8728","authenticated-orcid":false,"given":"Joanna S.","family":"Yi","sequence":"additional","affiliation":[{"name":"4Division of Pediatrics, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra M.","family":"Stevens","sequence":"additional","affiliation":[{"name":"4Division of Pediatrics, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Bataller","sequence":"additional","affiliation":[{"name":"2Division of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil","family":"Bhalla","sequence":"additional","affiliation":[{"name":"2Division of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetrios","family":"Petropoulos","sequence":"additional","affiliation":[{"name":"3Division of Pediatrics, Pediatric Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[{"name":"2Division of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[{"name":"2Division of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6917-2244","authenticated-orcid":false,"given":"Branko","family":"Cuglievan","sequence":"additional","affiliation":[{"name":"1Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[{"name":"2Division of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2025112011213114600_bib1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41588-023-01640-3","article-title":"A new genomic framework to categorize pediatric acute myeloid leukemia","volume":"56","author":"Umeda","year":"2024","journal-title":"Nat Genet"},{"issue":"3","key":"2025112011213114600_bib2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ajh.26822","article-title":"Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Shimony","year":"2023","journal-title":"Am J Hematol"},{"issue":"16","key":"2025112011213114600_bib3","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.3390\/cancers15164171","article-title":"Risk-stratified therapy for pediatric acute myeloid leukemia","volume":"15","author":"Tomizawa","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"suppl 6","key":"2025112011213114600_bib4","doi-asserted-by":"crossref","first-page":"e30584","DOI":"10.1002\/pbc.30584","article-title":"Children's Oncology Group's 2023 blueprint for research: myeloid neoplasms","volume":"70","author":"Cooper","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"2-3","key":"2025112011213114600_bib5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s44228-023-00041-x","article-title":"Venetoclax: a new partner in the novel treatment era for acute myeloid leukemia and myelodysplastic syndrome","volume":"5","author":"El-Cheikh","year":"2023","journal-title":"Clin Hematol Int"},{"issue":"9","key":"2025112011213114600_bib6","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/ajh.25556","article-title":"Acute myeloid leukemia drug development in the post-venetoclax era","volume":"94","author":"Pollyea","year":"2019","journal-title":"Am J Hematol"},{"issue":"10","key":"2025112011213114600_bib7","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.clinthera.2024.09.008","article-title":"Dosing of venetoclax in pediatric patients with relapsed acute myeloid leukemia: analysis of developmental pharmacokinetics and exposure-response relationships","volume":"46","author":"Badawi","year":"2024","journal-title":"Clin Ther"},{"issue":"13","key":"2025112011213114600_bib8","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1182\/bloodadvances.2023012041","article-title":"Venetoclax: a new player in the treatment of children with high-risk myeloid malignancies?","volume":"8","author":"Masetti","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"2025112011213114600_bib9","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","article-title":"Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study","volume":"21","author":"Karol","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"2025112011213114600_bib10","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.3390\/cancers15071983","article-title":"Venetoclax for acute myeloid leukemia in pediatric patients: a Texas Medical Center experience","volume":"15","author":"Trabal","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2025112011213114600_bib11","doi-asserted-by":"crossref","first-page":"e991","DOI":"10.1097\/MPH.0000000000002050","article-title":"Venetoclax and decitabine in pediatric refractory T-cell lymphoblastic lymphoma","volume":"43","author":"Baig","year":"2021","journal-title":"J Pediatr Hematol Oncol"},{"issue":"11","key":"2025112011213114600_bib12","doi-asserted-by":"crossref","first-page":"e31286","DOI":"10.1002\/pbc.31286","article-title":"Venetoclax for pediatric patients with newly diagnosed acute myeloid leukemia","volume":"71","author":"Gibson","year":"2024","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"2025112011213114600_bib13","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ajh.26601","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia","volume":"97","author":"DiNardo","year":"2022","journal-title":"Am J Hematol"},{"issue":"25","key":"2025112011213114600_bib14","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025112011213114600_bib15","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1046\/j.1365-2141.1998.00836.x","article-title":"IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial","volume":"102","author":"Fleischhack","year":"1998","journal-title":"Br J Haematol"},{"issue":"6","key":"2025112011213114600_bib16","first-page":"1823","article-title":"The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia","volume":"25","author":"Hubeek","year":"2004","journal-title":"Int J Oncol"},{"issue":"23","key":"2025112011213114600_bib17","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1200\/JCO.2017.72.6745","article-title":"Practical implications of the 2016 revision of the World Health Organization classification of lymphoid and myeloid neoplasms and acute leukemia","volume":"35","author":"Leonard","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025112011213114600_bib18","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"24","key":"2025112011213114600_bib19","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"27","key":"2025112011213114600_bib20","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J Clin Oncol"},{"issue":"18","key":"2025112011213114600_bib21","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1200\/JCO.21.01612","article-title":"Sorafenib in combination with standard chemotherapy for children with high allelic ratio FLT3\/ITD+ acute myeloid leukemia: a report from the Children's Oncology Group protocol AAML1031","volume":"40","author":"Pollard","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10","key":"2025112011213114600_bib22","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1182\/blood-2007-05-091942","article-title":"Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia","volume":"110","author":"Sung","year":"2007","journal-title":"Blood"},{"issue":"11","key":"2025112011213114600_bib23","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1007\/s00277-024-05939-x","article-title":"Investigation of infections status in pediatric patients with acute myeloid leukemia during the induction period-a retrospective study in two medical centers","volume":"103","author":"Xu","year":"2024","journal-title":"Ann Hematol"},{"issue":"suppl 1","key":"2025112011213114600_bib24","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1182\/blood-2022-157586","article-title":"Time to count recovery after post-remission chemotherapy in AML patients [abstract]","volume":"140","author":"Paras","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2025112011213114600_bib25","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1038\/s41375-018-0071-7","article-title":"Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012","volume":"32","author":"Rasche","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"2025112011213114600_bib26","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1182\/blood-2007-04-084293","article-title":"Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group","volume":"111","author":"Lange","year":"2008","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/21\/2608\/2421272\/blood_bld-2025-029391-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/21\/2608\/2421272\/blood_bld-2025-029391-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T16:21:43Z","timestamp":1763655703000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/21\/2608\/547366\/FLAG-IDA-plus-venetoclax-for-children-adolescents"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":26,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025,11,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025029391","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,20]]},"published":{"date-parts":[[2025,11,20]]}}}